Resistência ao tratamento nos transtornos de ansiedade: fobia social, transtorno de ansiedade generalizada e transtorno do pânico
OBJETIVOS: Os transtornos de ansiedade são condições psiquiátricas prevalentes que determinam importante prejuízo funcional, piora na qualidade de vida do indivíduo e um enorme custo social. Embora diversas medicações eficazes para os transtornos de ansiedade encontrem-se disponíveis, um número sign...
Saved in:
Published in | Revista brasileira de psiquiatria Vol. 29; no. suppl 2; pp. S55 - S60 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
01.10.2007
|
Online Access | Get full text |
Cover
Loading…
Abstract | OBJETIVOS: Os transtornos de ansiedade são condições psiquiátricas prevalentes que determinam importante prejuízo funcional, piora na qualidade de vida do indivíduo e um enorme custo social. Embora diversas medicações eficazes para os transtornos de ansiedade encontrem-se disponíveis, um número significativo de pacientes não responde adequadamente ao tratamento e muitos permanecem com sintomas residuais clinicamente significativos. O objetivo deste estudo é rever aspectos relacionados à resistência ao tratamento e estratégias farmacológicas no manejo dos transtornos de ansiedade resistentes ao tratamento. MÉTODO: Revisão narrativa. RESULTADOS: São discutidos os diversos aspectos conceituais relacionados à resistência ao tratamento, os possíveis preditores de resistência e, finalmente, algumas estratégias a serem utilizadas no manejo dos transtornos de ansiedade (incluindo transtorno de ansiedade social, transtorno de ansiedade generalizada e transtorno do pânico) que não respondem às abordagens terapêuticas convencionais. CONCLUSÃO: A resistência ao tratamento ainda é um desafio para a prática clínica que começa em conceitos não operacionalizados de resposta e resistência e termina na escassez de estudos controlados sobre estratégias de tratamento nesse último cenário clínico.
OBJECTIVES: Anxiety disorders are common psychiatric conditions that cause significant disability, poor quality of life and enormous social cost. Although treatments with demonstrable efficacy are available a great number of patients fail to respond or remains with clinically significant residual symptoms after treatment. The objective of this study is to review aspects related to treatment resistance and pharmacological strategies to deal with anxiety disorders resistant to treatment. METHOD: Narrative review. RESULTS: We discuss conceptual aspects related to treatment resistance or refractoriness, predictors of poor treatment outcome, and finally, some strategies to deal with anxiety disorders (including social anxiety disorder, generalized anxiety disorder and panic disorder) that do not respond to standard therapeutic interventions. CONCLUSION: Treatment resistance in anxiety disorders remains a challenge to clinical practice going from non standardized concepts of response and resistance to a paucity of controlled studies concerning therapeutic strategies. |
---|---|
AbstractList | OBJETIVOS: Os transtornos de ansiedade são condições psiquiátricas prevalentes que determinam importante prejuízo funcional, piora na qualidade de vida do indivíduo e um enorme custo social. Embora diversas medicações eficazes para os transtornos de ansiedade encontrem-se disponíveis, um número significativo de pacientes não responde adequadamente ao tratamento e muitos permanecem com sintomas residuais clinicamente significativos. O objetivo deste estudo é rever aspectos relacionados à resistência ao tratamento e estratégias farmacológicas no manejo dos transtornos de ansiedade resistentes ao tratamento. MÉTODO: Revisão narrativa. RESULTADOS: São discutidos os diversos aspectos conceituais relacionados à resistência ao tratamento, os possíveis preditores de resistência e, finalmente, algumas estratégias a serem utilizadas no manejo dos transtornos de ansiedade (incluindo transtorno de ansiedade social, transtorno de ansiedade generalizada e transtorno do pânico) que não respondem às abordagens terapêuticas convencionais. CONCLUSÃO: A resistência ao tratamento ainda é um desafio para a prática clínica que começa em conceitos não operacionalizados de resposta e resistência e termina na escassez de estudos controlados sobre estratégias de tratamento nesse último cenário clínico.
OBJECTIVES: Anxiety disorders are common psychiatric conditions that cause significant disability, poor quality of life and enormous social cost. Although treatments with demonstrable efficacy are available a great number of patients fail to respond or remains with clinically significant residual symptoms after treatment. The objective of this study is to review aspects related to treatment resistance and pharmacological strategies to deal with anxiety disorders resistant to treatment. METHOD: Narrative review. RESULTS: We discuss conceptual aspects related to treatment resistance or refractoriness, predictors of poor treatment outcome, and finally, some strategies to deal with anxiety disorders (including social anxiety disorder, generalized anxiety disorder and panic disorder) that do not respond to standard therapeutic interventions. CONCLUSION: Treatment resistance in anxiety disorders remains a challenge to clinical practice going from non standardized concepts of response and resistance to a paucity of controlled studies concerning therapeutic strategies. |
Author | Fontenelle, Leonardo F Menezes, Gabriela Bezerra de Versiani, Márcio Mululo, Sara |
Author_xml | – sequence: 1 givenname: Gabriela Bezerra de surname: Menezes fullname: Menezes, Gabriela Bezerra de organization: Universidade Federal do Rio de Janeiro, Brasil – sequence: 2 givenname: Leonardo F surname: Fontenelle fullname: Fontenelle, Leonardo F organization: Universidade Federal do Rio de Janeiro, Brasil – sequence: 3 givenname: Sara surname: Mululo fullname: Mululo, Sara organization: Universidade Federal do Rio de Janeiro, Brasil – sequence: 4 givenname: Márcio surname: Versiani fullname: Versiani, Márcio organization: Universidade Federal do Rio de Janeiro, Brasil |
BookMark | eNqdjzFuwkAQRVcRkYDAGdgDBDILxg5pERE1pF8N9jhaZHbQzjakzU0ouQYXw44iBEqXYjT_679f_K5qefak1MDAyExn8LI2U5MOkyRJxwAZAKT1QfKgOtegdaPbqiuyBRhnk9eso75XJE7i-eRzhxpZx4ARd-Qja8_SWC-RQ6ML0rVxVGBBb7rkTd0QrnvV8w13h-lP8hSwcl9YoKY7jPX-fPQu5556LLES6v_-J5W9Lz7my2EeWCRQaffB7TAcrAHbbLY_m-2fzZP_Ny_RBGXs |
Cites_doi | 10.4088/JCP.v67n0307 10.4088/JCP.v66n1016 10.1097/01.jcp.0000177853.15910.de 10.4088/JCP.v63n0113 10.1001/archpsyc.1994.03950010008002 10.4088/JCP.v67n0914 10.1176/appi.ajp.157.4.659-a 10.1056/NEJMsa043266 10.1097/00004714-200302000-00015 10.1097/00004850-199907000-00006 10.1097/00004714-199602000-00014 10.4088/JCP.v62n0813d 10.1186/1745-0179-2-35 10.1002/da.10086 10.1192/bjp.bp.105.012799 10.1016/S0006-3223(97)00390-9 10.1080/08039480310002110 10.4088/PCC.v02n0301 10.1097/00004850-200501000-00002 10.1002/da.20050 10.3109/15622970009150563 10.1002/da.10096 10.4088/JCP.v65n1213 10.1016/0165-0327(96)00030-4 10.1097/00004850-200015060-00004 10.1097/01.jcp.0000248620.34541.bc 10.1176/appi.ajp.163.3.548 10.1176/appi.ajp.158.10.1725 10.1192/bjp.173.1.54 10.1097/01.jcp.0000195108.01898.17 10.1007/s00213-004-1957-9 10.1097/00004714-200010000-00011 10.1176/appi.ajp.160.4.749 10.1016/S0193-953X(05)70254-9 10.1002/hup.421 10.4088/JCP.v68n0221e 10.1176/ajp.155.7.992 10.1097/01.jcp.0000155821.74832.f9 10.1016/j.jad.2005.05.003 10.1017/S1092852900022148 10.1017/S1092852900022392 10.1177/026988110201600412 10.1055/s-2004-832600 10.1016/j.biopsych.2005.07.005 10.1590/S1516-44462006000400003 10.1097/01.jcp.0000084025.22282.84 10.1177/070674379804300109 10.1038/sj.mp.4001852 10.1097/00005053-198608000-00006 10.1017/S1092852900022355 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1590/S1516-44462007000600004 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Psychology |
EISSN | 1516-4446 |
EndPage | S60 |
ExternalDocumentID | 10_1590_S1516_44462007000600004 |
GroupedDBID | 0R~ 0SF 123 29P 2WC 457 5VS 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO AAYXX ABDBF ABDHV ABIVO ABMAC ABXHO ACGFO ACGFS ACHQT ADBBV ADEZE ADVLN AEGXH AENEX AEXQZ AGHFR AIAGR AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ APOWU AZFZN B14 BAWUL BCNDV CITATION CS3 DIK DU5 E3Z EBD EBS EFA EJD ESX FAEIB FDB GROUPED_DOAJ GX1 HYE HZ~ IPNFZ IXB KQ8 M~E NCXOZ O-L O9- OK1 P2P PGMZT RIG RNS RPM RSC SCD SSZ TR2 XSB ~8M |
ID | FETCH-crossref_primary_10_1590_S1516_444620070006000043 |
ISSN | 1516-4446 |
IngestDate | Fri Aug 23 03:09:14 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | suppl 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-crossref_primary_10_1590_S1516_444620070006000043 |
ParticipantIDs | crossref_primary_10_1590_S1516_44462007000600004 |
PublicationCentury | 2000 |
PublicationDate | 2007-10-00 |
PublicationDateYYYYMMDD | 2007-10-01 |
PublicationDate_xml | – month: 10 year: 2007 text: 2007-10-00 |
PublicationDecade | 2000 |
PublicationTitle | Revista brasileira de psiquiatria |
PublicationYear | 2007 |
References | Sepede G (ref19) 2006; 26 Cournoyer J (ref59) 1986; 31 Snyderman SH (ref16) 2005; 25 Katerndahl DA (ref22) 2003; 17 Simon NM (ref17) 2006; 67 Menza MA (ref52) 2001; 27 Etxebeste M (ref65) 2000; 157 Kinrys G (ref50) 2003; 18 Zwanzger P (ref61) 2001; 62 Worthington JJ 3rd (ref32) 2005; 20 Pallanti S (ref38) 2006; 2 Simon NM (ref46) 2002; 7 Van Ameringen M (ref23) 2004; 9 Pallanti S (ref14) 2006; 2 Pollack MH (ref21) 2003; 23 Pollack MH (ref15) 1998; 155 Hollifield M (ref39) 2005; 21 Hirschmann S (ref13) 2000; 20 Buch S (ref41) 2007; 68 Kessler RC (ref3) 1994; 51 Mitte K (ref9) 2005; 88 Van Ameringen M (ref45) 1996; 39 Schwartz TL (ref40) 2002; 36 Aarre TF (ref42) 2003; 57 Wittchen HU (ref6) 2001; 24 Liebowitz MR (ref27) 2002; 63 Ontiveros A (ref57) 1992; 17 Stein MB (ref26) 2005; 177 Altamura AC (ref47) 1999; 14 Versiani M (ref44) 2000; 1 Pollack MH (ref35) 2006; 59 Johnson MR (ref31) 1998; 43 Barnett SD (ref48) 2002; 16 Blanco C (ref10) 2003; 18 Londborg PD (ref28) 1998; 173 Sheikh JI (ref29) 2000; 15 Mitte K (ref8) 2005; 25 Dannon PN (ref62) 2002; 17 Cerra D (ref60) 2006; 163 Nemeroff CB (ref34) 2005; 66 Khaldi S (ref37) 2003; 23 Brawman-Mintzer O (ref54) 2005; 66 Bystrisky A (ref5) 2006; 11 Ballenger JC (ref1) 2000; 2 Keller MB (ref12) 2005; 66 Stein DJ (ref43) 2005 Pollack MH (ref53) 2006; 59 Stein DJ (ref4) 2004; 9 Baetz M (ref63) 1998; 43 Bandelow B (ref20) 2006; 67 Van Ameringen M (ref49) 2004; 65 Pollack MH (ref11) 2007 Kessler RC (ref2) 2005; 352 Robinson HM (ref30) 2006; 28 Boerner RJ (ref55) 1995; 22 Blier P (ref33) 2005; 66 Tiffon L (ref56) 1994; 55 Hetem LA (ref58) 1996; 16 Brawman-Mintzer O (ref18) 2005; 66 Ipser JC (ref7) 2006; 4 Tesar GE (ref36) 1986; 174 Baldwin DS (ref25) 2006; 189 Chao IL (ref64) 2004; 37 Stein MB (ref51) 2001; 158 Rickels K (ref24) 2003; 160 |
References_xml | – volume: 67 start-page: 381 issn: 0160-6689 issue: 3 year: 2006 ident: ref17 article-title: An open-label trial of risperidone augmentation for refractory anxiety disorders publication-title: J Clin Psychiatry doi: 10.4088/JCP.v67n0307 contributor: fullname: Simon NM – volume: 66 start-page: 1321 issn: 0160-6689 issue: 10 year: 2005 ident: ref54 article-title: Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo- controlled study publication-title: J Clin Psychiatry doi: 10.4088/JCP.v66n1016 contributor: fullname: Brawman-Mintzer O – volume: 25 start-page: 497 issn: 0271-0749 issue: 5 year: 2005 ident: ref16 article-title: Open-label pilot study of ziprasidone for refractory generalized anxiety disorder publication-title: J Clin Psychopharmacol doi: 10.1097/01.jcp.0000177853.15910.de contributor: fullname: Snyderman SH – volume: 63 start-page: 66 issn: 0160-6689 issue: 1 year: 2002 ident: ref27 article-title: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder publication-title: J Clin Psychiatry doi: 10.4088/JCP.v63n0113 contributor: fullname: Liebowitz MR – volume: 51 start-page: 8 issn: 0003-990X issue: 1 year: 1994 ident: ref3 article-title: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1994.03950010008002 contributor: fullname: Kessler RC – volume: 67 start-page: 1428 issn: 0160-6689 issue: 9 year: 2006 ident: ref20 article-title: What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? publication-title: J Clin Psychiatry doi: 10.4088/JCP.v67n0914 contributor: fullname: Bandelow B – volume: 157 start-page: 659 issn: 0002-953X issue: 4 year: 2000 ident: ref65 article-title: Olanzapine and panic attacks publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.157.4.659-a contributor: fullname: Etxebeste M – volume: 352 start-page: 2515 issn: 0028-4793 issue: 24 year: 2005 ident: ref2 article-title: Prevalence and treatment of mental disorders, 1990 to 2003 publication-title: N Engl J Med doi: 10.1056/NEJMsa043266 contributor: fullname: Kessler RC – volume: 66 start-page: 5 year: 2005 ident: ref12 article-title: Issues in treatment-resistant depression publication-title: J Clin Psichiatry contributor: fullname: Keller MB – volume: 23 start-page: 100 issn: 0271-0749 issue: 1 year: 2003 ident: ref37 article-title: Pelc I. Usefulness of olanzapine in refractory panic attacks publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-200302000-00015 contributor: fullname: Khaldi S – volume: 22 start-page: 30 issn: 0303-4259 issue: 1 year: 1995 ident: ref55 article-title: Treatment refractory panic disorder -success of a combined treatment with imipramine, moclobemide and behavior therapy publication-title: Psychiatr Prax contributor: fullname: Boerner RJ – issn: 1091-4269 year: 2007 ident: ref11 article-title: Novel treatment approaches for refractory anxiety disorders publication-title: Depress Anxiety contributor: fullname: Pollack MH – volume: 14 start-page: 239 issn: 0268-1315 issue: 4 year: 1999 ident: ref47 article-title: Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders publication-title: Int Clin Psychopharmacol doi: 10.1097/00004850-199907000-00006 contributor: fullname: Altamura AC – volume: 16 start-page: 77 issn: 0271-0749 issue: 1 year: 1996 ident: ref58 article-title: Addition of d-fenfluramine to benzodiazepines produces a marked improvement in refractory panic disorder-a case report publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-199602000-00014 contributor: fullname: Hetem LA – volume: 62 start-page: 656 issn: 0160-6689 issue: 8 year: 2001 ident: ref61 article-title: Tiagabine improves panic and agoraphobia in panic disorder patients publication-title: J Clin Psychiatry doi: 10.4088/JCP.v62n0813d contributor: fullname: Zwanzger P – volume: 2 start-page: 35 year: 2006 ident: ref14 article-title: Resistant social anxiety disorder response to Escitalopram publication-title: Clin Pract Epidemiol Ment Health doi: 10.1186/1745-0179-2-35 contributor: fullname: Pallanti S – volume: 18 start-page: 169 issn: 0268-1315 issue: 3 year: 2003 ident: ref50 article-title: Valproic acid for the treatment of social anxiety disorder publication-title: Int Clin Psychopharmacol contributor: fullname: Kinrys G – volume: 66 start-page: 13 issn: 0160-6689 year: 2005 ident: ref34 article-title: Use of atypical antipsychotic in refractory depression and anxiety publication-title: J Clin Psychiatry contributor: fullname: Nemeroff CB – volume: 17 start-page: 98 issn: 1091-4269 issue: 2 year: 2003 ident: ref22 article-title: Predictors and outcomes in people told that they have panic attacks publication-title: Depress Anxiety doi: 10.1002/da.10086 contributor: fullname: Katerndahl DA – volume: 189 start-page: 264 issn: 0007-1250 year: 2006 ident: ref25 article-title: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study publication-title: Br J Psychiatry doi: 10.1192/bjp.bp.105.012799 contributor: fullname: Baldwin DS – volume: 43 start-page: 306 issn: 0006-3223 issue: 4 year: 1998 ident: ref31 article-title: Abnormal peripheral benzodiazepine receptor density associated with generalized social phobia publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(97)00390-9 contributor: fullname: Johnson MR – volume: 57 start-page: 313 issue: 4 year: 2003 ident: ref42 article-title: Phenelzine efficacy in refractory social anxiety disorder: a case series publication-title: Nord J Psychiatry doi: 10.1080/08039480310002110 contributor: fullname: Aarre TF – volume: 2 start-page: 71 issue: 3 year: 2000 ident: ref1 article-title: Anxiety and depression: optimizing treatments publication-title: Prim Care Companion J Clin Psychiatry doi: 10.4088/PCC.v02n0301 contributor: fullname: Ballenger JC – volume: 20 start-page: 9 issn: 0268-1315 issue: 1 year: 2005 ident: ref32 article-title: Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients publication-title: Int Clin Psychopharmacol doi: 10.1097/00004850-200501000-00002 contributor: fullname: Worthington JJ 3rd – volume: 21 start-page: 33 issn: 1091-4269 issue: 1 year: 2005 ident: ref39 article-title: Potential effectiveness and safety of olanzapine in refractory panic disorder publication-title: Depress Anxiety doi: 10.1002/da.20050 contributor: fullname: Hollifield M – volume: 1 start-page: 27 issue: 1 year: 2000 ident: ref44 article-title: A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia) publication-title: World J Biol Psychiatry doi: 10.3109/15622970009150563 contributor: fullname: Versiani M – volume: 18 start-page: 29 issn: 1091-4269 issue: 1 year: 2003 ident: ref10 article-title: Pharmacological treatment of social anxiety disorder: a meta-analysis publication-title: Depress Anxiety doi: 10.1002/da.10096 contributor: fullname: Blanco C – volume: 65 start-page: 1674 issn: 0160-6689 issue: 12 year: 2004 ident: ref49 article-title: An open-label trial of topiramate in the treatment of generalized social phobia publication-title: J Clin Psychiatry doi: 10.4088/JCP.v65n1213 contributor: fullname: Van Ameringen M – volume: 39 start-page: 115 issn: 0165-0327 issue: 2 year: 1996 ident: ref45 article-title: Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia publication-title: J Affect Disord doi: 10.1016/0165-0327(96)00030-4 contributor: fullname: Van Ameringen M – volume: 15 start-page: 335 issn: 0268-1315 issue: 6 year: 2000 ident: ref29 article-title: The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies publication-title: Int Clin Psychopharmacol doi: 10.1097/00004850-200015060-00004 contributor: fullname: Sheikh JI – volume: 27 start-page: 207 issn: 0271-0749 issue: 2 year: 2001 ident: ref52 article-title: An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder publication-title: J Clin Psychopharmacol doi: 10.1097/01.jcp.0000248620.34541.bc contributor: fullname: Menza MA – volume: 163 start-page: 548 issn: 0002-953X issue: 3 year: 2006 ident: ref60 article-title: Trimipramine for refractory panic attacks publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.163.3.548 contributor: fullname: Cerra D – volume: 158 start-page: 1725 issn: 0002-953X issue: 10 year: 2001 ident: ref51 article-title: Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebocontrolled, crossover study publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.158.10.1725 contributor: fullname: Stein MB – volume: 173 start-page: 54 issn: 0007-1250 year: 1998 ident: ref28 article-title: Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation publication-title: Br J Psychiatry doi: 10.1192/bjp.173.1.54 contributor: fullname: Londborg PD – volume: 26 start-page: 45 issn: 0271-0749 issue: 1 year: 2006 ident: ref19 article-title: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial publication-title: J Clin Psychopharmacol doi: 10.1097/01.jcp.0000195108.01898.17 contributor: fullname: Sepede G – volume: 177 start-page: 280 issn: 0033-3158 issue: 3 year: 2005 ident: ref26 article-title: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder publication-title: Psychopharmacology doi: 10.1007/s00213-004-1957-9 contributor: fullname: Stein MB – volume: 4 start-page: CD005473 year: 2006 ident: ref7 article-title: Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders publication-title: Cochrane Database Syst Rev contributor: fullname: Ipser JC – volume: 20 start-page: 556 issn: 0271-0749 issue: 5 year: 2000 ident: ref13 article-title: Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-200010000-00011 contributor: fullname: Hirschmann S – volume: 31 start-page: 335 issn: 0706-7437 issue: 4 year: 1986 ident: ref59 article-title: Rapid response of a disorder to the addition of lithium carbonate: panic resistant to tricyclic antidepressants publication-title: Can J Psychiatry contributor: fullname: Cournoyer J – volume: 160 start-page: 749 issn: 0002-953X issue: 4 year: 2003 ident: ref24 article-title: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.160.4.749 contributor: fullname: Rickels K – volume: 36 start-page: 53 issn: 0048-5764 issue: 2 year: 2002 ident: ref40 article-title: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series publication-title: Psychopharmacol Bull contributor: fullname: Schwartz TL – issue: 3 year: 2005 ident: ref43 article-title: Pharmacotherapy for social anxiety disorder publication-title: The Cochrane Library contributor: fullname: Stein DJ – volume: 24 start-page: 617 issue: 4 year: 2001 ident: ref6 article-title: Epidemiology, patterns of comorbidity, and associated disabilities of social phobia publication-title: Psychiatr Clin N Am doi: 10.1016/S0193-953X(05)70254-9 contributor: fullname: Wittchen HU – volume: 17 start-page: 329 issue: 7 year: 2002 ident: ref62 article-title: The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study publication-title: Hum Psychopharmacol doi: 10.1002/hup.421 contributor: fullname: Dannon PN – volume: 2 start-page: 35 year: 2006 ident: ref38 article-title: Resistant social anxiety disorder response to Escitalopram publication-title: Clin Pract Epidemol Ment Health doi: 10.1186/1745-0179-2-35 contributor: fullname: Pallanti S – volume: 68 start-page: 335 issn: 0160-6689 issue: 2 year: 2007 ident: ref41 article-title: Successful use of phenelzine in treatment-resistant panic disorder publication-title: J Clin Psychiatry doi: 10.4088/JCP.v68n0221e contributor: fullname: Buch S – volume: 155 start-page: 992 issn: 0002-953X issue: 7 year: 1998 ident: ref15 article-title: Gabapentin as a potential treatment for anxiety disorders publication-title: Am J Psychiatry doi: 10.1176/ajp.155.7.992 contributor: fullname: Pollack MH – volume: 25 start-page: 141 issn: 0271-0749 issue: 2 year: 2005 ident: ref8 article-title: A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder publication-title: J Clin Psychopharmacol doi: 10.1097/01.jcp.0000155821.74832.f9 contributor: fullname: Mitte K – volume: 88 start-page: 27 issn: 0165-0327 issue: 1 year: 2005 ident: ref9 article-title: A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia publication-title: J Affect Disord doi: 10.1016/j.jad.2005.05.003 contributor: fullname: Mitte K – volume: 7 start-page: 655 issue: 9 year: 2002 ident: ref46 article-title: Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients publication-title: CNS Spectr doi: 10.1017/S1092852900022148 contributor: fullname: Simon NM – volume: 66 start-page: 1321 issn: 0160-6689 issue: 10 year: 2005 ident: ref18 article-title: Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study publication-title: J Clin Psychiatry doi: 10.4088/JCP.v66n1016 contributor: fullname: Brawman-Mintzer O – volume: 9 start-page: 753 issue: 10 year: 2004 ident: ref23 article-title: Optimizing treatment in social phobia: a review of treatment resistance publication-title: CNS Spectr doi: 10.1017/S1092852900022392 contributor: fullname: Van Ameringen M – volume: 16 start-page: 365 issn: 0269-8811 issue: 4 year: 2002 ident: ref48 article-title: Efficacy of olanzapine in social anxiety disorder: a pilot study publication-title: J Psychopharmacol doi: 10.1177/026988110201600412 contributor: fullname: Barnett SD – volume: 37 start-page: 239 issn: 0031-7098 issue: 5 year: 2004 ident: ref64 article-title: Olanzapine augmentation in panic disorder: a case report publication-title: Pharmacopsychiatry doi: 10.1055/s-2004-832600 contributor: fullname: Chao IL – volume: 59 start-page: 211 issn: 0006-3223 issue: 3 year: 2006 ident: ref53 article-title: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2005.07.005 contributor: fullname: Pollack MH – volume: 28 start-page: 263 issue: 4 year: 2006 ident: ref30 article-title: Dopamine and social anxiety disorder publication-title: Rev Bras Psiquiatr doi: 10.1590/S1516-44462006000400003 contributor: fullname: Robinson HM – volume: 55 start-page: 66 issn: 0160-6689 issue: 2 year: 1994 ident: ref56 article-title: Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients publication-title: J Clin Psychiatry contributor: fullname: Tiffon L – volume: 23 start-page: 250 issn: 0271-0749 issue: 3 year: 2003 ident: ref21 article-title: Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder publication-title: J Clin Psychopharmacol doi: 10.1097/01.jcp.0000084025.22282.84 contributor: fullname: Pollack MH – volume: 59 start-page: 211 issn: 0006-3223 issue: 3 year: 2006 ident: ref35 article-title: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2005.07.005 contributor: fullname: Pollack MH – volume: 43 start-page: 73 issn: 0706-7437 issue: 1 year: 1998 ident: ref63 article-title: Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy publication-title: Can J Psychiatry doi: 10.1177/070674379804300109 contributor: fullname: Baetz M – volume: 11 start-page: 805 issn: 1359-4184 issue: 9 year: 2006 ident: ref5 article-title: Treatment-resistant anxiety disorders publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001852 contributor: fullname: Bystrisky A – volume: 174 start-page: 477 issn: 0022-3018 issue: 8 year: 1986 ident: ref36 article-title: Successful use of clonazepam in patients with treatment-resistant panic disorder publication-title: J Nerv Ment Dis doi: 10.1097/00005053-198608000-00006 contributor: fullname: Tesar GE – volume: 17 start-page: 78 issn: 1180-4882 issue: 2 year: 1992 ident: ref57 article-title: Sodium valproate and clonazepam for treatment-resistant panic disorder publication-title: J Psychiatry Neurosci contributor: fullname: Ontiveros A – volume: 9 start-page: 715 issue: 10 year: 2004 ident: ref4 article-title: Unresolved questions about treatment-resistant anxiety disorders publication-title: CNS Spectr doi: 10.1017/S1092852900022355 contributor: fullname: Stein DJ – volume: 66 start-page: 30 issn: 0160-6689 year: 2005 ident: ref33 article-title: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety publication-title: J Clin Psychiatry contributor: fullname: Blier P |
SSID | ssj0027387 |
Score | 3.5518885 |
Snippet | OBJETIVOS: Os transtornos de ansiedade são condições psiquiátricas prevalentes que determinam importante prejuízo funcional, piora na qualidade de vida do... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | S55 |
Title | Resistência ao tratamento nos transtornos de ansiedade: fobia social, transtorno de ansiedade generalizada e transtorno do pânico |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZKWVgQT_GWBzZTSNI8WrYWKAipDBQktspJXKkSSkrSDnTlnzDyN_qnGLmzUyflIShLlFqXs5v75HvGR8ghd4RrCM-quIFAB8V0K37P5RUPU7kGr1mhbJ3QvnGv7u3rB-ehVHovVC2Nhv5xMP72u5L_SBXGQK74lewcktVMYQDuQb5wBQnD9U8yvhUpSEnmuht4bAbjMfZ8GHIM-cUsilP8GWEBJN6HmCpIwebEs3arDdaLfXhGRc3xVee0M6TYZRkjV_0xDzkTM2QxG8jprQgQVTR0MecAhicDZzyFjaefcOQ5SPtPI9kaRGuDNjAfq73qkvvguD9y1oSRRD6RK0kstcckgwwkCPAfEpi8lePlcaSSSBjino7KYKBqWsXacp1mEqjCMx3p8HTNnN6cAUm2nYUsxTdj2Y6exVAUclPsjsqswibdUQcDZ_q-o_oZfFElTh1rLzt6AlyRPL4GzeBce04rBj4pVV3qiE4WsOpKRt0vjBbIouXVHadMFhvN82YrDxZUZXNHPX1WmwisTn5YU8GyKphIdytkOfNtaEMBdZWURLRGlrSKfV4nLwqxkzdEK-UxzdFKAaG0gFYaCqoheEolVqnC6lGBboaMFpFKxQxZTAeTV0TpBvFaF3dnV5Xp3-gO1Ikr3V9eYnWTlKM4EluEgvXqhLWeXTUC1w4Cw_dq9cDnvl3vhWZgmtvEmJf7zvyP7JKlHMB7pDxMRmIfjNehf5DJ-UAGfz4AosGbQA |
link.rule.ids | 315,786,790,870,27955,27956 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Resist%C3%AAncia+ao+tratamento+nos+transtornos+de+ansiedade%3A+fobia+social%2C+transtorno+de+ansiedade+generalizada+e+transtorno+do+p%C3%A2nico&rft.jtitle=Revista+brasileira+de+psiquiatria&rft.au=Menezes%2C+Gabriela+Bezerra+de&rft.au=Fontenelle%2C+Leonardo+F&rft.au=Mululo%2C+Sara&rft.au=Versiani%2C+M%C3%A1rcio&rft.date=2007-10-01&rft.issn=1516-4446&rft.eissn=1516-4446&rft.volume=29&rft.issue=suppl+2&rft.spage=S55&rft.epage=S60&rft_id=info:doi/10.1590%2FS1516-44462007000600004&rft.externalDBID=n%2Fa&rft.externalDocID=10_1590_S1516_44462007000600004 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1516-4446&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1516-4446&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1516-4446&client=summon |